As on Thursday, Harvard Bioscience Inc (NASDAQ: HBIO) got off with the flyer as it spiked 12.07% to $0.45, before settling in for the price of $0.41 at the close. Taking a more long-term approach, HBIO posted a 52-week range of $0.28-$3.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of -18.10% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -18.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.67%. This publicly-traded company’s shares outstanding now amounts to $44.21 million, simultaneously with a float of $37.41 million. The organization now has a market capitalization sitting at $20.07 million. At the time of writing, stock’s 50-day Moving Average stood at $0.4313, while the 200-day Moving Average is $1.3023.
Harvard Bioscience Inc (HBIO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Medical Instruments & Supplies industry. Harvard Bioscience Inc’s current insider ownership accounts for 15.39%, in contrast to 58.46% institutional ownership.
Harvard Bioscience Inc (HBIO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.01 per share during the current fiscal year.
Harvard Bioscience Inc’s EPS increase for this current 12-month fiscal period is 16.67% and is forecasted to reach 0.06 in the upcoming year.
Harvard Bioscience Inc (NASDAQ: HBIO) Trading Performance Indicators
Let’s observe the current performance indicators for Harvard Bioscience Inc (HBIO). It’s Quick Ratio in the last reported quarter now stands at 0.40. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.22. Similarly, its price to free cash flow for trailing twelve months is now 52.82.
In the same vein, HBIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.32, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be 0.06 at the market close of one year from today.
Technical Analysis of Harvard Bioscience Inc (HBIO)
Through scrutinizing the latest numbers posted by the [Harvard Bioscience Inc, HBIO], it can be observed that its last 5-days Average volume of 1.4 million was lower the volume of 5.82 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 31.72% While, its Average True Range was 51.20%.
Raw Stochastic average of Harvard Bioscience Inc (HBIO) in the period of the previous 100 days is set at 24.35%, which indicates a major fall in contrast to 50.71% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0366 that was lower than 0.0648 volatility it exhibited in the past 100-days period.
